An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

This study has been completed.
Sponsor:
Collaborators:
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Bayer
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Ryan Sullivan, M.D., Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01078961
First received: March 1, 2010
Last updated: June 7, 2016
Last verified: January 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2016
  Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Publications: